Table 1.
Inhibition of HIV-1 binding to the DC-SIGN receptor expressed on Raji cells
|
HIV-1 envelope pseudovirus |
 |
b Percentage inhibition | ||
| c GRFT | CV-N | SVN | ||
| Subtype C | ||||
| COT9.6 | 56.4 ± 1.0 | 69.1 ± 1.8 | 34.8 ± 18.9 | |
| CAP63.A9J | 37.9 ± 3.2 | 68.4 ± 2.9 | 39.1 ± 11.9 | |
| Du156.12 | 27.7 ± 5.9 | 34.1 ± 2.0 | 19.7 ± 0.9 | |
| Du151.2 | 16.5 ± 7.6 | 46.6 ± 0.4 | 28.5 ± 6.0 | |
| COT6.15 | 9.8 ± 3.7 | 46.7 ± 22.5 | 43.9 ± 3.2 | |
| Median | 27.7 | 46.7 | 34.8 | |
| Subtype B | ||||
| CAAN5342.A2 | 66.8 ± 0.6 | 89.7 ± 0.3 | 50.3 ± 13.0 | |
| PVO.4 | 64.3 ± 23.2 | 82.3 ± 20.6 | 57.9 ± 26.4 | |
| QH0692.42 | 40.1 ± 11.1 | 63.7 ± 2.6 | 50.8 ± 11.7 | |
| Median | 64.3 | 82.3 | 50.8 | |
a
Mannose-rich glycosylation sites were identified from the amino acid sequence of each envelope clone (related to HxB2) based on a study using monomeric gp120 (Leonard et al., 1990). Absent glycans are indicated by black boxes.
b
The percentage inhibition was tested at 345 nM, 450 nM and 1030 nM of GRFT, CV-N and SVN, respectively.
c
Viruses are ranked according to their sensitivity to GRFT.